Rohan Katipally to Combined Modality Therapy
This is a "connection" page, showing publications Rohan Katipally has written about Combined Modality Therapy.
Connection Strength
0.119
-
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
Score: 0.041
-
Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer. Cancer J. 2024 Jul-Aug 01; 30(4):256-263.
Score: 0.041
-
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
Score: 0.036